Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial

Tesamorelin, a synthetic growth hormone-releasing hormone, is indicated for the reduction of visceral adipose tissue (VAT) in people with HIV. Here, we performed a post hoc analysis of participants receiving tesamorelin for 26 weeks in a phase III clinical trial. Efficacy data were compared between...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical and translational science 2023, Vol.7 (1), p.e40-e40, Article e40
Main Authors: Rahman, Farah, McLaughlin, Taryn, Mesquita, Pedro, Morin, Josee, Potvin, Diane, De Chantal, Marilyn, Aberg, Judith A
Format: Article
Language:English
Subjects:
Abdomen
Adipose tissue
antiretrovirals
Body composition
Body fat
Body mass index
Brief Report
Clinical Research
Clinical trials
Double-blind studies
Drug therapy
FDA approval
Growth hormone-releasing hormone
Growth hormones
HIV
Human immunodeficiency virus
Insulin-like growth factors
lipohypertrophy
Males
Patients
tesamorelin
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Tesamorelin, a synthetic growth hormone-releasing hormone, is indicated for the reduction of visceral adipose tissue (VAT) in people with HIV. Here, we performed a post hoc analysis of participants receiving tesamorelin for 26 weeks in a phase III clinical trial. Efficacy data were compared between individuals with and without dorsocervical fat, stratified by tesamorelin response. Among tesamorelin responders, VAT and waist circumference (WC) decreased in both dorsocervical fat groups and did not statistically differ (VAT = 0.657, WC = 0.093). These data demonstrate that tesamorelin is equally effective and should be considered in the treatment of excess VAT regardless of the presence of dorsocervical fat.
ISSN:2059-8661
2059-8661
DOI:10.1017/cts.2022.515